The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
List view / Grid view
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
First-of-its-kind study uses a multi-omics approach to provide a list of causal candidate genes associated with alcohol use disorder (AUD).
UK researchers have created a metal-based molecule that inhibits the build-up of Alzheimer’s-associated peptide, amyloid-β, in lab tests.
US researchers have identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that could be used against these targets.
In brain tissues, researchers have shown that two different nanosized polyoxoniobate molecules can inhibit the assembly of amyloid plaques.
A new gene therapy that introduced SynCav1 to the brains of Alzheimer's mouse models was shown to preserve neuronal and synaptic plasticity.
A novel sensitive label-free imaging method has been developed to visualise brain samples using an FxClear-based tissue clearing technique.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.
Oral doses of a new drug named CA administered to mouse models led to improvements in Alzheimer's disease, including memory.
Researchers have developed a stem cell therapy that could treat the damage caused by dementia by launching a repair response.
A study has shown that treatments to reduce levels of hydrogen sulphide (H2S) in the brain may help to prevent dementia.
Researchers have reported that nano-micelles can be used to efficiently deliver CRISPR-Cas9 to edit genes in the brains of mice.
Researchers have shown that an siRNA nanomedicine can target BACE1 in a mouse model of Alzheimer's, restoring cognitive capacity.
A team has shown that inhibiting the soluble epoxide hydrolase (sEH) enzyme in murine models can prevent the cognitive deterioration associated with Alzheimer's.